In 2016, cannabis legalization still felt uncertain. Each ballot initiative carried real political weight. Each governor’s signature felt like it could shift the direction of the conversation. Around that time, after more than a decade working in government, I began paying closer attention to how reform was actually unfolding across the country.
From the outside, it often looked like momentum. In reality, it felt more like a long process of figuring things out as we went.
RELATED: Here’s how America really feels about legalizing psilocybin
Medical programs expanded. Adult-use markets followed. States that had long resisted reform began to change course. Public opinion moved steadily in one direction. Today, most Americans live in a state where cannabis is legal in some form. That story is often told as inevitable. It did not feel inevitable at the time.
What became clear over the years is that reform moves quickly. Systems do not.
Every state built its own regulatory structure. Licensing caps in one place, vertical integration mandates in another. Municipal opt-outs that left entire regions without access. Tax regimes that sometimes made legal participation barely viable. Social equity programs that reflected sincere attempts to address past harm, but often struggled to function as intended. Above it all, federal prohibition remained unchanged, shaping everything from banking access to the day-to-day mechanics of operating legally.
Legalization created momentum. Governance created the maze that followed.
The next wave
Psychedelics now appear to be entering a similar phase of public attention, though through a very different historical pathway. For many Americans, this moment feels new, driven by clinical research and a growing willingness to rethink how mental health is treated. But the story stretches back much further. Indigenous ceremonial use predates modern drug policy by centuries. Mid-20th century scientific exploration was followed by political backlash, cultural anxiety, and sweeping federal scheduling that effectively halted research for decades.
RELATED: Ketamine therapy is having a moment. Here’s what it really is – and who it’s for
Today’s resurgence reflects a convergence of forces. Researchers are again studying substances such as psilocybin, MDMA, and LSD. Veterans’ groups and mental health advocates are pushing the conversation forward. Policymakers are beginning to engage with frameworks that would have seemed politically implausible not long ago. State-level discussions now range from regulated psilocybin services to medical pilot programs, task forces examining therapeutic access, and early legislative interest in compounds like ibogaine.
The pace of change is uneven, and that is part of the reality of reform. It is unfolding across different substances, regulatory philosophies, and political coalitions at the same time.
Cannabis offered a vivid demonstration of how quickly public consensus can shift — and how slowly durable policy systems can take shape. Early enthusiasm eventually ran into implementation realities. Regulatory bottlenecks emerged. Affordability became a central issue. Local resistance complicated the rollout. The tension between public health goals and commercial market dynamics proved harder to resolve than many expected. None of this erased the significance of legalization. But it did complicate the story.
A similar story
Psychedelic policy is developing under different conditions. The conversation is often framed first around therapeutic access rather than consumer markets. Institutional medicine, research universities, and federal regulatory pathways are playing a more visible role. Still, some familiar structural questions are already emerging.
Cost is one. In places where regulated psychedelic services are permitted, supervised sessions can cost thousands of dollars. That may reflect the caution of early regulatory design, but it also raises practical questions about who reform is ultimately intended to serve. If access is shaped primarily by the ability to pay, the public health promise driving much of the current momentum may be difficult to fully realize.
RELATED: Meet the trauma survivor quietly shaping Colorado’s psychedelic future
Federal-state alignment is another. Cannabis has spent years operating within a landscape of legal contradiction. Psychedelics could encounter similar tensions if state experimentation moves faster than federal rescheduling or approval decisions. Those contradictions are not abstract. They shape investment, research timelines, enforcement priorities, and public confidence.
There are also quieter institutional questions that tend to matter more over time than at the moment reform becomes politically viable. How agencies coordinate rulemaking. How timelines are communicated. How expectations are set among patients, practitioners, and the public. Reform generates attention. Institutions determine whether anything lasting emerges from it.
A decade spent watching cannabis policy evolve does not offer a blueprint for psychedelics. The historical trajectories are different. The regulatory models will likely diverge in important ways. But the experience does shape how one thinks about what comes after reform gains traction.
Legal change is not self-executing. It unfolds through budgets, bureaucratic capacity, political negotiation, and shifting public expectations. Momentum can open doors. What follows determines who is actually able to walk through them.
RELATED: Cannabis users are chasing relief, not a high
Psychedelics are moving from the margins of cultural debate toward the center of policy experimentation. That transition carries both promise and responsibility. If policymakers, researchers, and advocates approach this phase with a clearer understanding of how reform plays out in practice, there is an opportunity to build systems that are more coherent from the outset.
Momentum can change the conversation. Whether reform delivers on its promise depends on what is built once the urgency fades and the harder work of governance begins.
*This article was submitted by an unpaid guest contributor. The opinions or statements within do not necessarily reflect those of GreenState or HNP. The author is solely responsible for the content.